|
1
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Motzer RJ, Jonasch E, Agarwal N, Bhayani
S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman
M, et al: Kidney cancer, version 2.2017, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 15:804–834.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Escudier B, Porta C, Schmidinger M,
Riou-Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A: ESMO
Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
27:v58–v68. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wang C, Thudium KB, Han M, Wang XT, Huang
H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al: In
vitro characterization of the anti-PD-1 antibody nivolumab,
BMS-936558, and in vivo toxicology in non-human primates. Cancer
Immunol Res. 2:846–856. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sonpavde G, Hutson TE and Rini BI:
Axitinib for renal cell carcinoma. Expert Opin Investig Drugs.
17:741–748. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
US Department Of Health And Human
Services: Common terminology criteria for adverse events (CTCAE)
version 4.0. United States, National Cancer Institute, Sept 15,
2009. http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5X7.pdf.
|
|
7
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Motzer RJ, Rini BI, McDermott DF, Redman
BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S,
Logan TF, et al: Nivolumab for metastatic renal cell carcinoma:
Results of a randomized phase II trial. J Clin Oncol. 33:1430–1407.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tomita Y, Fukasawa S, Shinohara N,
Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, et
al: Nivolumab versus everolimus in advanced renal cell carcinoma:
Japanese subgroup analysis from the checkmate 025 study. Jpn J Clin
Oncol. 47:639–646. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
National Comprehensive Cancer Network:
Clinical practice guidelines in oncology: Kidney Cancer. version 2.
JNCCN · June 2017.
|
|
11
|
McDermott DF, Drake CG, Sznol M, Choueiri
TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ,
Puzanov I, et al: Survival, durable response, and long-term safety
in patients with previously treated advanced renal cell carcinoma
receiving nivolumab. J Clin Oncol. 33:2013–2020. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
De Giorgi U, Cartenì G, Giannarelli D,
Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R,
Bearz A, et al: Safety and efficacy of nivolumab for metastatic
renal cell carcinoma: Real-World results from an expanded access
programme. BJU Int. 123:98–105. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Grimm SE, Armstrong N, Ramaekers BLT,
Pouwels X, Lang S, Petersohn S, Riemsma R, Worthy G, Stirk L, Ross
J, et al: Nivolumab for treating metastatic or unresectable
urothelial cancer: An evidence review group perspective of a NICE
single technology appraisal. Pharmacoeconomics. 37:655–667.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zargar M, McFarlane T, Chan KKW and Wong
WWL: Cost-Effectiveness of nivolumab in recurrent metastatic head
and neck squamous cell carcinoma. Oncologist. 23:225–233.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Matter-Walstra K, Schwenkglenks M, Aebi S,
Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R and
Gautschi O: Swiss Group for Clinical Cancer Research: A
cost-effectiveness analysis of nivolumab versus docetaxel for
advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol.
11:1846–1855. 2016.PubMed/NCBI View Article : Google Scholar
|
